Saratoga Research & Investment Management Continues to Hold Position in Pfizer, Inc. (PFE)
Saratoga Research & Investment Management continued to hold its position in Pfizer, Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,970 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Saratoga Research & Investment Management’s holdings in Pfizer were worth $234,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of PFE. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer in the first quarter worth $121,000. Cascade Investment Advisors Inc. raised its holdings in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the last quarter. Patten Group Inc. raised its holdings in shares of Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 252 shares during the last quarter. Finally, Acropolis Investment Management LLC raised its holdings in shares of Pfizer by 6.7% in the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 352 shares during the last quarter. 68.98% of the stock is owned by institutional investors.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by insiders.
PFE has been the subject of a number of research analyst reports. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. UBS AG reaffirmed a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. BMO Capital Markets reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $38.26.
Shares of Pfizer, Inc. (PFE) opened at 36.42 on Friday. The firm has a market cap of $216.60 billion, a price-to-earnings ratio of 26.64 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.60. The company’s 50-day moving average is $35.56 and its 200 day moving average is $33.83.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.64 EPS. On average, analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.51%. Pfizer’s payout ratio is currently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.